The benefits of Alzheimer’s drug lecanemab (Leqembi) are too small to justify the cost of providing the treatment to NHS patients, the UK regulator has ruled. This was the decision by the National Institute for Health and Care Excellence (NICE) in draft guidance on the drug. Lecanemab is for slowing progression in mild cognitive impairment […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!